↓ Figure 1. Post-bromocriptine change in
bleeding, pain, and stress.
| Journal of Clinical Gynecology and Obstetrics, ISSN 1927-1271 print, 1927-128X online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Clin Gynecol Obstet and Elmer Press Inc |
| Journal website https://jcgo.elmerpub.com |
Original Article
Volume 14, Number 4, December 2025, pages 155-160
Role of Vaginal Bromocriptine in Symptomatic Management of Adenomyosis
Figure
Tables
| Features | N = 52, n (%) |
|---|---|
| aData expressed as median (interquartile range). bData expressed as mean ± SD. LNG-IUDs: levonorgestrel intrauterine device; NPRS: numeric pain rating scale; NSAIDs: nonsteroidal anti-inflammatory drugs; PBLAC: pictorial blood loss assessment chart; PSS: perceived stress scale. | |
| Age (years)a | 39 (36, 45) |
| Body mass index (kg/m2)b | 25.6 ± 4.3 |
| History of infertility | 7 (13.5) |
| Previous cesarean section or uterine surgery | 31 (59.6) |
| Nullipara | 9 (17.3) |
| Primipara | 3 (5.8) |
| Multipara | 40 (76.9) |
| PBLAC score < 200 | 4 (7.8) |
| PBLAC score 200 to 300 | 32 (61.5) |
| PBLAC score > 300 | 16 (30.7) |
| Moderate pain (NPRS score 4 to 6) | 4 (7.8) |
| Severe pain (NPRS score 7 to 10) | 48 (92.2) |
| Low stress (PSS score 0 to 13) | 2 (4) |
| Moderate stress (PSS score 14 to 26) | 46 (88.4) |
| High stress (PSS score 27 to 40) | 4 (7.8) |
| Prior medical treatment with NSAIDs | 50 (96.2) |
| Prior medical treatment with tranexamic acid | 41 (78.8) |
| Oral contraceptive | 18 (34.6) |
| Prior treatment with LNG-IUDs | 21 (40.4) |
| Anemia | 46 (88.5) |
| Prolactin level (n = 24) (normal value < 25 ng/mL)b | 24.3 ± 9.4 |
| CA125 (n = 22) (normal value = 0 to 35 U/mL)b | 72.2 ± 5.4 |
| Parameters | Baseline (n = 52) | 3 months (n = 52) | P value | 6 moths (n = 52) | P value | 9 months (n = 50) | P vale | 12 months (n = 50) | P value |
|---|---|---|---|---|---|---|---|---|---|
| IQR: interquartile range; NPRS: numeric pain rating scale; PBLAC: pictorial blood loss assessment chart; PSS: perceived stress scale. | |||||||||
| PBLAC score (median, IQR) | 235 (220 - 320) | 232 (220 - 315) | 0.806 | 115 (80 - 200) | < 0.001 | 90 (80 - 190) | < 0.001 | 95 (75 - 170) | < 0.001 |
| NPRS score (median, IQR) | 8 (7 - 9) | 7 (6 - 7) | < 0.001 | 4 (4 - 5) | < 0.001 | 4 (3 - 5) | 0.20 | 2.5 (2 - 3) | < 0.001 |
| PSS score (median, IQR) | 22 (20 - 24) | 16 (14 - 18) | < 0.001 | 11.5 (11 - 13) | < 0.001 | 9 (9 - 10) | < 0.001 | 8 (7 - 9) | < 0.001 |
| Features | At baseline (n = 52) | At 6-month follow-up of persistence of previous lesion (n = 52) | P value |
|---|---|---|---|
| ns: not significant. | |||
| Myometrial cysts, n (%) | 19 (36.5) | 17 (32.7) | ns |
| Hyperechogenic islands, n (%) | 36 (69.2) | 35 (67.3) | ns |
| Echogenic sub-endometrial lines and buds, n (%) | 34 (65.4) | 32 (61.5) | ns |
| Globular uterus, n (%) | 36 (69.2) | 31 (59.6) | ns |
| Asymmetrical thickening of the myometrium, n (%) | 41(78.8) | 34 (65.4) | 0.01 |
| Translesional vascularity, n (%) | 40 (76.9) | 29 (55.8) | 0.001 |
| Irregular or interrupted junctional zone, n (%) | 29 (55.7) | 25 (48.1) | 0.045 |
| Parallel/fan-shaped shadowing, n (%) | 35 (67.3) | 34 (65.4) | ns |